Recent studies also shows that co-treatment of JQ1 and FLT3-inhibitor, FLT3-TKI, can greatly attenuate the expression of c-MYC, BCL2, and CDK4/6, meanwhile synergistically induce apoptosis of cultured and primary CD34(+) human AML blast progenitor cells (BPC) expressing [62]. The gene discussed is FLT3; the disease is acute myeloid leukemia.